YuanSheng Venture Capital Portfolio Companies Featured in Hurun Future Unicorns: Global Gazelles Index 2025 and Other Prestigious Lists

Jan 27, 2026 15:12 CST Updated 15:12

PegBio

Developer of Innovative Therapies for Chronic Diseases

Percutek Therapeutics

Developer of Minimally Invasive Cardiovascular Treatment Devices

Click on the "blue words" above to follow more exciting content.

Recently, Hurun Research Institute, the world's largest compiler of entrepreneurial rankings, released the "Hurun Future Unicorns: Global Gazelles Index 2025" in Beijing Yizhuang. The report selected 819 high-growth companies globally that were founded after 2000 and are most likely to reach a unicorn valuation of $1 billion within three years (by the end of 2028). Among them, 278 companies are from China, including 46 biotech companies, and Guangzhou has 13 companies on the list. China’s Hurun Gazelle companies are mainly in the biotech and semiconductor industries, accounting for 30% of the national total.

Eight portfolio companies of YuanBio Venture Capital have successfully made it to this year's list. Meanwhile, PegBio has been honored as one of the top 10 Hurun China Gazelles since its listing in 2019. Percutek Therapeutics, Changmu Valley Medical, Goodhealth Bio, Haobo Pharmaceuticals, Ark Biopharma, Ease Medicine, ClinChoice, and Visen Medical have been listed on the "2025 Hurun Future Unicorns: Global Gazelle Companies List."

END

About YuanSheng Ventures

Yuansheng Venture CapitalIs an investment institution focused on early and growth-stage healthcare sectors, based in Suzhou BioBAY with a global reach. To date, it has completed investments in over 200 outstanding enterprises in the life sciences and health sector, spanning four key areas: novel drug development, medical devices, in vitro diagnostics and precision medicine, as well as future healthcare technologies, achieving substantial investment returns. Among these, 20 companies have gone public on capital markets such as the Hong Kong Stock Exchange and the STAR Market. OrbiMed China has been repeatedly ranked among the Top 10 venture capital funds in China’s healthcare sector and recognized as one of the most active healthcare investment institutions in China. With a team of seasoned professional investors and a world-class scientific advisory board, OrbiMed China possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry. Leveraging professionalism, focus, and abundant industry resources, we are committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.